Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 10 January 2026 - 11 January 2026

Olema Pharmaceuticals stock jumps 10% into JPM conference week: what OLMA traders are watching next

Olema Pharmaceuticals stock jumps 10% into JPM conference week: what OLMA traders are watching next

New York, Jan 10, 2026, 20:48 ET — Market closed Shares of Olema Pharmaceuticals Inc (OLMA.O) jumped nearly 10% on Friday, closing at $28.08 and extending the biotech’s strong rally. The clinical-stage breast cancer drugmaker has been on a notable upswing recently. This move is crucial as next week marks a pivotal period for small and mid-cap biotech firms. Executives will scatter around San Francisco for the annual J.P. Morgan Healthcare Conference, while investors demand solid timelines instead of lofty promises. Olema’s CEO Sean P. Bohen will speak on Jan. 13 at 11:15 a.m. PT (2:15 p.m. ET). The company
11 January 2026
····
Revolution Medicines stock in focus as Merck buyout talk hangs over RVMD into JPMorgan week

Revolution Medicines stock in focus as Merck buyout talk hangs over RVMD into JPMorgan week

New York, January 10, 2026, 20:11 EST — The market has closed. Revolution Medicines (RVMD.O) wrapped up Friday with a 10.7% gain, closing at $118.64. The cancer-drug developer remains in focus amid ongoing takeover buzz heading into next week. Shares fluctuated between $109.88 and $125.79, with roughly 20.8 million shares changing hands. Why this matters now: Dealmakers have flocked to San Francisco for the J.P. Morgan Healthcare Conference, where big pharma is hunting for growth and bankers are pitching bigger targets once again. Jeremy Meilman from JPMorgan noted that some deals moving forward “could have had more regulatory risk in
11 January 2026
····
NovaBay Pharmaceuticals stock doubles as NBY volatility flares again — what to watch next

NovaBay Pharmaceuticals stock doubles as NBY volatility flares again — what to watch next

New York, January 10, 2026, 18:35 EST — Market closed Shares of NovaBay Pharmaceuticals Inc soared on Friday, closing up roughly 103% at $19.16. Over 10 million shares changed hands, market data showed. NovaBay is back on momentum screens before the next U.S. session, trading in a price range unseen for over a year. Why it matters now: NovaBay’s size means its price often moves on volume, not news. When that shift hits before a weekend, the following open becomes a gauge of who’s left to buy. The stock moved between $9.69 and $19.95 in regular trading, then was last
11 January 2026
·····
Novo Nordisk Class B stock rises after Amazon adds Wegovy pill — what to watch before earnings

Novo Nordisk Class B stock rises after Amazon adds Wegovy pill — what to watch before earnings

Copenhagen, Jan 10, 2026, 20:43 CET — The market has closed. Novo Nordisk A/S Class B shares (NOVOb.CO) rose 3% on Friday after Amazon Pharmacy announced it had started selling the company’s Wegovy weight-loss pill, expanding availability for U.S. patients just days following the drug’s market debut. The Copenhagen-traded stock closed at 381.45 Danish crowns. (Reuters) The launch of Amazon’s new channel is crucial, as those initial weeks often shape prescription growth and pricing control. Investors have swiftly knocked stocks at the first hint of weakening demand or discounts extending past just starter doses. It also places a busy storefront
10 January 2026
····
Novartis AG stock stays near a 52-week high after Florida radioligand plant plan

Novartis AG stock stays near a 52-week high after Florida radioligand plant plan

Zurich, Jan 10, 2026, 20:36 CET — Market closed Novartis AG (NOVN.S) is set to open a radioligand therapy manufacturing plant in Winter Park, Florida, part of its broader $23 billion U.S. production expansion. Shares of the Swiss drugmaker ended Friday up 0.25% at 114.04 Swiss francs, just shy of their 52-week peak of 114.64. CEO Vas Narasimhan described the facility as “an important step,” while Florida’s commerce chief J. Alex Kelly welcomed the move as an opportunity to bring in “world class innovators.” Radioligand therapy, known as RLT, combines a tumour-targeting molecule with a therapeutic radioisotope, directing radiation straight
10 January 2026
·····
Roche stock in focus after MediLink cancer-drug deal as investors eye Jan. 29 results

Roche stock in focus after MediLink cancer-drug deal as investors eye Jan. 29 results

ZURICH, Jan 10, 2026, 17:45 CET — Market closed Roche Holding (ROG.S) shares edged up on Friday, boosted by news that China’s MediLink Therapeutics secured another licensing deal with the Swiss pharma giant for a cancer drug candidate. Roche participation shares closed 0.4% higher at 340.80 Swiss francs on the SIX Swiss Exchange. (Medilink Therapeutics) Why it matters now: Roche is stepping up dealmaking and licensing efforts to bolster its oncology pipeline, and investors will be eager to see how fast these moves turn into new products. The timing also raises questions about spending discipline, as major R&D investments come
10 January 2026
·····
AbbVie stock slips into weekend after $1.3 billion charge resets guidance; JPM conference looms

AbbVie stock slips into weekend after $1.3 billion charge resets guidance; JPM conference looms

NEW YORK, January 10, 2026, 11:17 AM EST — The market has closed. Shares of AbbVie Inc slipped 1.8% to close Friday at $220.08, wrapping up a choppy session marked by shifting guidance and takeover rumors. AbbVie disclosed in a regulatory filing that it anticipates around $1.3 billion in acquired in-process research and development (IPR&D) and milestone expenses in Q4—costs associated with upfront charges for buying or licensing drug projects. This will slash earnings by approximately 71 cents per share. The company also cut its Q4 adjusted EPS forecast to $2.61-$2.65 from $3.32-$3.36 and trimmed its full-year 2025 adjusted EPS
10 January 2026
·····
Johnson & Johnson stock dips on Trump drug-price deal — what to watch before Monday

Johnson & Johnson stock dips on Trump drug-price deal — what to watch before Monday

New York, January 10, 2026, 10:58 ET — Market closed Johnson & Johnson shares fell 0.7% on Friday, closing at $204.39. The company said it reached an agreement with the U.S. government to lower drug prices in exchange for exemptions from tariffs. (reuters.com) The timing matters: drugmakers are heading into another round of pricing battles abroad, particularly in Europe, after agreeing to U.S. price concessions tied to what other wealthy countries pay. “You can’t force the Europeans to just all of a sudden spend more. But the deals do give the companies negotiating power,” said Marshall Gordon, a senior research
10 January 2026
····
Eli Lilly stock slides 2%: Zepbound trial data, TuneLab AI tie-up and what’s next for LLY

Eli Lilly stock slides 2%: Zepbound trial data, TuneLab AI tie-up and what’s next for LLY

NEW YORK, January 10, 2026, 10:08 EST — Market closed Eli Lilly & Co shares fell 2% on Friday to $1,063.56, underperforming a stronger broader market and extending a two-day slide. The stock is now 6.21% below its 52-week high of $1,133.95 set on Thursday, while trading volume ran below its recent average. The pullback lands as investors re-price big pharma growth names ahead of a busy stretch of healthcare headlines, from deal chatter to new drug readouts. Bankers and lawyers have been heading to San Francisco for next week’s J.P. Morgan Healthcare Conference, betting the tone on mergers could
10 January 2026
·····
Liquidia stock jumps 13% after $148M Yutrepia sales update; what investors watch next

Liquidia stock jumps 13% after $148M Yutrepia sales update; what investors watch next

New York, Jan 10, 2026, 09:08 ET — Market closed Key points: Liquidia Corporation shares climbed 12.9% on Friday to $35.86, extending a sharp run after the drugmaker laid out preliminary 2025 sales for its inhaled pulmonary hypertension drug, Yutrepia. The update matters because Yutrepia is now the engine of the story, not a promise. It is also a test of whether Liquidia can pry patients away from entrenched treatments in a market led by United Therapeutics’ treprostinil franchise. Liquidia said Yutrepia net product sales were about $90.1 million in the fourth quarter and $148.3 million for 2025, with 74%
10 January 2026
·····
Hims & Hers stock slides as Amazon adds Wegovy pill, raising fresh pricing fears

Hims & Hers stock slides as Amazon adds Wegovy pill, raising fresh pricing fears

NEW YORK, Jan 10, 2026, 06:23 EST — Market closed Hims & Hers Health, Inc. (HIMS) shares fell 6.4% on Friday to $31.69, with about 25 million shares changing hands. The stock is down roughly 11% over the past two sessions as investors weighed Amazon Pharmacy’s move into Novo Nordisk’s Wegovy weight-loss pill business. (StockAnalysis) That matters now because Hims has pushed hard into GLP-1 weight-loss drugs — medicines that mimic a gut hormone to curb appetite — and a lot of demand in the category still comes from patients paying cash. Hims lists a “compounded GLP-1” program starting at
10 January 2026
·····
GSK stock: $50m Noetik deal and Jemperli royalty lawsuit sharpen focus on Feb 4 results

GSK stock: $50m Noetik deal and Jemperli royalty lawsuit sharpen focus on Feb 4 results

New York, Jan 10, 2026, 03:42 EST — Market closed AnaptysBio said it filed a motion asking a U.S. court to dismiss part of a claim by GSK plc’s oncology unit, escalating a dispute over royalties tied to sales of cancer drug Jemperli, a PD-1 inhibitor — a kind of immunotherapy that helps the immune system attack tumours. Tesaro sued AnaptysBio in Delaware in November seeking to terminate a 2014 licence and halve royalty and milestone payments, while AnaptysBio countersued and pointed to trials involving rival PD-1 drugs including Merck’s Keytruda; the case is set for a July 14–17 trial
10 January 2026
·····
1 … 18 19 20 21 22 … 56

Stock Market Today

Walmart stock jumps to $131 as traders brace for CPI and Feb. 19 earnings

Walmart stock jumps to $131 as traders brace for CPI and Feb. 19 earnings

7 February 2026
Walmart shares rose 3.3% Friday to $131.18, up 10% since Jan. 30, as the Dow closed above 50,000 for the first time. The retailer’s market value crossed $1 trillion this week. Investors await January inflation data on Feb. 13 and Walmart’s quarterly results on Feb. 19 for signs of continued momentum.
Caterpillar stock price jumps 7% to $726 as Dow cracks 50,000 — what matters next week

Caterpillar stock price jumps 7% to $726 as Dow cracks 50,000 — what matters next week

7 February 2026
Caterpillar shares surged 7.1% to $726.20 Friday, driving the Dow above 50,000 for the first time. The move erased recent losses and followed insider selling by Group President Bob De Lange earlier in the week. Deere and CNH Industrial also gained as investors rotated into industrial stocks. Markets await next week’s U.S. jobs and inflation data.
Amazon stock slides as $200B AI spending plan meets cautious profit outlook

Amazon stock slides as $200B AI spending plan meets cautious profit outlook

7 February 2026
Amazon shares fell 9% Friday after the company announced plans for $200 billion in 2026 capital spending, mainly for AWS and AI, and issued a first-quarter profit outlook below estimates. The stock drop could erase $200 billion in market value. Fourth-quarter net sales rose 14% to $213.4 billion, while free cash flow declined due to higher spending on AI infrastructure.
Go toTop